Lernik Ohanjanian, Senior Medical Director at Miltenyi Biomedicine, shared on LinkedIn:

“We are standing on the cusp of revolution in drug discovery and development, with artificial intelligence (AI) emerging as a transformative tool to improve cancer patient outcomes.

Let’s use AI responsibly in target identification and validation, acceleration of clinical trials, personalization of treatments, enhancing drug formulations, streamlining regulatory approvals and above all improving patient outcomes.”

Source: Lernik Ohanjanian/LinkedIn